Market accessOfficial

ANSM updates list of contrast agents available in France amid continuing supply tensions

🇫🇷 ANSM · Tue 10 Nov 2026

The French regulator's refreshed situation update lists contrast media currently available from Bayer and Bracco, and says tensions have persisted since a change in distribution circuit.

ANSM, the French medicines agency, updated its situation report on contrast agent supply on 10 November 2026. The page was first published on 30 April 2025. It sets out which contrast products marketed in France are available from the laboratories, to help healthcare professionals and patients find them.

The agency says the tables are built from data supplied by the manufacturers and will be updated regularly. It describes contrast agents as medicines that are swallowed or injected and used in medical imaging to make the structure of the organs under examination easier to see.

ANSM says tensions have persisted for several months, since a change in the distribution circuit. It adds that it continues to work with the laboratories concerned to cover patients' needs. The page does not give the causes of the tensions, quantities or expected timelines for resolution.

The November update lists available products by laboratory, with CIP code, brand, presentation and active substance. Bayer's entries cover Gadovist (gadobutrol) in vials and prefilled syringes, Primovist (gadoxetic acid) prefilled syringes, and Ultravist 300 and 370 (iopromide) in several vial sizes. Bracco's entries include Iomeron (iomeprol) at several iodine concentrations, in vials of various sizes. The source text supplied for this report is cut off partway through the Bracco list, so the full set of products should be checked on the ANSM page.

What it means for your team

  • Supply-continuity teams should check the ANSM tables, which are based on manufacturer data, against their own stock and ordering records for specific CIP codes.
  • Products missing from the list should not be assumed unavailable without confirming with the marketing authorisation holder, as the source text provided is incomplete.
  • The page gives no causes, volumes or recovery dates, so mitigation planning needs direct contact with suppliers and further ANSM communication.
  • The tables are to be refreshed regularly, so teams tracking imaging-agent availability should watch for further updates.

Official source: ANSM ↗

Article written by VigiEye from the official source (ANSM). AI-assisted; check the source before acting.

More Market access All →